Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Cardiotoxicity 2Breast Neoplasms 2Renal Insufficiency, Chronic 1Kidney Neoplasms 1Heart Failure 1Carcinoma, Renal Cell 1

Interventions

Standard of Care 2Rituximab 2Carvedilol 2sacubitril and valsartan sodium hydrate drug combination 1pegfilgrastim 1obinutuzumab 1empagliflozin 1dapagliflozin 1acalabrutinib 1Vincristine 1Vascular Stiffness 1Valsartan 1Specimen Handling 1Pulse Wave Analysis 1Prednisolone 1Practice Guidelines as Topic 1Palliative Care 1Nutrition Assessment 1Mesenchymal Stem Cell Transplantation 1Lenalidomide 1Health Information Exchange 1Exercise 1Eplerenone 1Electronic Health Records 1Electrocardiography 1Echocardiography 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Cardiac Resynchronization Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Failure × empagliflozin × 1 year × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡